Carcinosarcoma of the uteri as a third diagnosed malignancy – case report and the review of treatment modality Case report

Article Sidebar

PDF (Język Polski)


Published: Dec 31, 2013
Keywords:
carcinosarcoma uteri, malignant mixed mullerian tumor, multiple primary malignancies

Main Article Content

Małgorzarta Kuc-Rajca
Klinika Onkologii, Centrum Medyczne Kształcenia Podyplomowego, Europejskie Centrum Zdrowia Otwock
Anna Walaszkowska-Czyż
Klinika Onkologii, Centrum Medyczne Kształcenia Podyplomowego, Europejskie Centrum Zdrowia Otwock

Abstract

Uterine carcinosarcoma is a rare epithelial malignant neoplasm. It is aggressive uterine cancer with poor survival rates. The use of adjuvant treatment seems to be beneficial. Chemotherapy should be based on paclitaxel and ifosfamide. There are ongoing clinical trials to identify potentially more active agents. The GOG phase II trial evaluating paclitaxel and carboplatin have demonstrated significant activity and acceptable toxicity. Multiple primary malignancies are diagnosed rarely. The presented patient was treated because of three independent malignancies: kidney, breast cancer and uterine carcinosarcoma.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Kuc-Rajca M, Walaszkowska-Czyż A. Carcinosarcoma of the uteri as a third diagnosed malignancy – case report and the review of treatment modality. OncoReview [Internet]. 2013Dec.31 [cited 2024Nov.23];3(4(12):274-7. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/350
Issue
Vol 3 No 4(12) (2013)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. FIGO Committee on Gynecologic Oncology: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynecol. Obstet. 2009; 105: 103-104.
2. Prat J.: FIGO staging for uterine sarcomas. Special editorial. Int. J. Gynecol. Obstet. 2009; 104: 177-178.
3. McCluggage W.G.: Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int. J. Gynecol. Cancer 2002; 12: 687-690.
4. Sartori E., Bazzurini L., Gadducci A. et al.: Carcinosarcoma of the uterus: A clinicopathological multicenter CTF study. Gynecol. Oncol. 1997; 67: 70-75.
5. Rose P.G., Piver M.S., Tsukada Y. et al.: Patterns of metastasis in uterine sarcoma: An autopsy study. Cancer 1989; 63: 935-938.
6. NCCN Guidelines. Uterine Neoplasms, Version 3.2012. Online: www.nccn.org.
7. Reed N.S., Mangioni C., Malmström H. et al.: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur. J. Cancer 2008; 44(6): 808-18.
8. Wolfson A.H., Brady M.F., Rocereto T. et al.: A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol. Oncol. 2007; 107(2): 177-85.
9. Chi D.S., Mychalczak B., Saigo P.E. et al.: The Role of Whole-Pelvic Irradiation in the Treatment of Early-Stage Uterine Carcinosarcoma. Gynecol. Oncol. 1997; 65: 493-498.
10. Sutton G., Brunetto V.L., Kilgore L. et al.: A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol. Oncol. 2000; 79(2): 147-53.
11. Homesley H.D., Filiaci V., Markman M. et al.: Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2007; 25(5): 526-31.
12. Powell M.A., Filiaci V.L., Rose P.G. et al.: Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J. Clin. Oncol. 2010; 28(16): 2727-31.
13. Ramondetta L.M. et al.: A phase II multicenter trial of paclitaxel and carboplatin in women with advanced or recurrent malignant mixed mullerian tumors (MMMT) of the uterus. J. Clin. Oncol. 2007; 25(supl.): 296s (abstr. 5589).
14. Hoskins P.J., Le N., Ellard S. et al.: Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors: The British Columbia Cancer Agency experience. Gynecol. Oncol. 2008; 108: 58-62.
15. El-Nashar S.A., Mariani A.: Uterine carcinosarcoma. Clin. Obstet. Gynecol. 2011; 54(2): 292-304.
16. Grundmann R.T., Meyer F.: [Second primary malignancy among cancer survivors-epidemiology, prognosis and clinical relevance]. Zentralbl. Chir. 2012; 137: 565-574.
17. Huang X.Y., Huang Z.L., Huang J. et al.: A case of multiple primary malignancies and investigation of family history. Oncol. Lett. 2012; 4: 931-934